STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 04:33 PM

Ainos Q1 Net Loss $2.46M; Revenue $161; Operating Expenses Down 30%

AI Summary

Ainos, Inc. reported a net loss of $2.46 million for the first quarter ended March 31, 2026, an improvement from a $3.29 million net loss in the prior year's quarter. Revenue for the quarter was $161, a substantial decrease from $106,207 year-over-year, reflecting a transition towards industrial and infrastructure-focused AI Nose deployments. Operating expenses decreased by approximately 30% to $2.28 million, and the company strengthened its balance sheet with a NT$90 million (approximately US$2.8 million) financing arrangement. Ainos highlighted continued progress in commercializing its AI Nose technology across semiconductor and healthcare infrastructure markets, with ongoing deployment and pilot activities.

Key Highlights

  • Net loss for Q1 2026 was $2.46 million, an improvement from $3.29 million in Q1 2025.
  • Revenue for Q1 2026 was $161, a significant decrease from $106,207 in Q1 2025.
  • Operating expenses declined approximately 30% year-over-year to $2.28 million.
  • Strengthened balance sheet with NT$90 million (approximately US$2.8 million) financing.
  • Continued deployment activities for approximately 1400 AI Nose systems in semiconductor manufacturing.
  • Cash and cash equivalents increased to $2,841,422 as of March 31, 2026, from $417,353 at December 31, 2025.
AIMD
Biotechnology: Pharmaceutical Preparations
Ainos, Inc.

Price Impact